News stories about OraSure Technologies (NASDAQ:OSUR) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. OraSure Technologies earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned news coverage about the medical instruments supplier an impact score of 46.9277396136826 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Several equities research analysts have recently issued reports on the stock. Zacks Investment Research raised shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a research report on Friday, February 9th. Canaccord Genuity reaffirmed a “buy” rating and set a $24.00 price objective on shares of OraSure Technologies in a research report on Friday, February 2nd. ValuEngine raised shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Friday, March 2nd. Finally, BidaskClub cut shares of OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 15th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. OraSure Technologies has a consensus rating of “Buy” and a consensus target price of $22.25.
Shares of OraSure Technologies (OSUR) opened at $18.25 on Monday. The stock has a market cap of $1,112.65, a price-to-earnings ratio of 35.79, a PEG ratio of 5.09 and a beta of 1.60. OraSure Technologies has a 1 year low of $10.75 and a 1 year high of $23.01.
In related news, Director Stephen S. Phd Tang sold 23,333 shares of OraSure Technologies stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $17.97, for a total transaction of $419,294.01. Following the sale, the director now directly owns 59,749 shares in the company, valued at approximately $1,073,689.53. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Brian Smith sold 20,000 shares of OraSure Technologies stock in a transaction on Friday, February 16th. The stock was sold at an average price of $17.97, for a total transaction of $359,400.00. Following the sale, the executive vice president now owns 28,075 shares in the company, valued at $504,507.75. The disclosure for this sale can be found here. 6.40% of the stock is owned by company insiders.
COPYRIGHT VIOLATION WARNING: This story was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3257648/orasure-technologies-osur-earning-somewhat-favorable-press-coverage-study-finds.html.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.